36 results about "Phenformin" patented technology

The invention relates to novel AMPK agonist containing compositions that are adapted for localised use in treating inflammation and / or pain due to disease or injury in a human or animal. The novel compositions of the invention are useful in the treatment of a variety of conditions including osteoarthritis (OA), synovitis, tendonitis, desmitis; cystitis, osteitis and laminitis. Routes of administration include intra-articular, direct injection into tissues, instillation, retrograde perfusion and topical. AMPK agonists which can be used include AICAR, metformin, phenformin, A-769662, resveratrol, berberine and polyphenols.

A hypoglycemic medicine for treating diabetes and repairing the damaged beta-pancreatic island cells contains the natural amino acid (taurine, cysteine and methionine) and the biguaride medicine (dimethyl biguaride and phenylethyl biguaride).

The present invention relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administered in the treatment of cancer, and more specifically, the present invention suggests anticancer agents capable of creating the synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as anticancer agents in the present invention are sorafenib, vemurafenib, irinotecan, cisplatin, parclitaxel, and doxorubicin, and each of the aforementioned anticancer agents, when co-administered as a triple-drug combination with gossypol and phenformin, can provide a significant synergistic effect in terms of the effects of suppressing the proliferation of cancer and killing cancer cells, comparedto each mono-drug treatment group and a dual-drug treatment group of gossypol + phenformin.

A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

The present invention relates to a pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients. Specifically, the combinative treatment with gossypol and phenformin was verified to have a significantly higher anticancer activity than a single treatment with gossypol and phenformin alone. Therefore, the pharmaceutical composition of the present invention containing gossypol and phenformin having a synergetic anticancer activity can be favorably used for cancer treatment.

The invention belongs to the field of medicine and particularly relates to biguanide derivatives, pharmaceutical composition, a preparation method and an application. The biguanide derivatives are compounds with the structure shown in the description, or pharmaceutically acceptable salts, solvates, isomers, esters and predrugs of the compounds. The compounds can remarkably inhibit proliferation and migration of tumor cells, IC50 is greatly lower than that of metformin and phenformin before derivatization, the compound 11 has the highest activity, and activity of the compounds in UMUC3, T24 andA2780 cells is more than 300-800 times that of metformin, and the compounds have good application prospect in antitumor drugs.

The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agents capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.

The invention discloses a compound Chinese patent medicine which is prepared by combining Chinese medicines and western medicines, in particular to a medicine used for treating diabetes mellitus. The medicine takes the western medicines with the function of lowering blood sugar and the Chinese medicines used for preventing and treating chronic complicating disease as the main ingredients, and theingredients particularly include: 14-18g of radix astragali paste, 16-20g of radix puerariae powder, 10-14g of angelica paste, 0.1-1g of salvia miltiorrhiza paste, 1-4g of rhizoma atractylodis paste,0.05-0.5g of glibenclamide powder and 1.25-3.75g of phenformin powder; the preparation method is as follows: high-quality medicinal materials of radix astragali, angelica, salvia miltiorrhiza and rhizoma atractylodis are selected and decocted with water for 2 times, one hour per time; the dreg is removed, and the juice is taken and stands still for 8-12 hours; after being clarified, supernatant fluid is taken and is decocted into paste; radix puerariae is pulverized and sieved by a 120 meshes fine screen to remove fibers and prepare powder; then radix astragali paste and angelica paste as well as radix puerariae powder, salvia miltiorrhiza paste and glibenclamide powder, rhizoma atractylodis paste and phenformin powder are evenly stirred respectively and prepared into dried granules whichare loaded into capsules after being evenly blended. By adopting a traditional processing technique, the product of the invention contains a variety of medicine ingredients for reducing blood sugar and preventing and treating various complicating diseases, has precise prescription, long lasting drug effect, remarkable curative effect and safe and reliable performance.

To provide an inhibitor of melanin decomposition, which inhibits decomposition of melanin in keratinocytes to accelerate accumulation of melanin in skin and hair.An inhibitor of melanin decomposition in keratinocytes, comprising at least one selected from the group consisting of a plant extract containing berberine or a salt thereof, berberine or a salt thereof, proguanil or a salt thereof and phenformin or a salt thereof, as an active ingredient.

A compound hypoglycemic medicine in the form of tablet, capsule, particles, or powder for decreasing the sugar, pressure, fat and viscosity of blood is prepared from the fine powder of sulfonylurea medicines, the fine powder of berberine hydrochloride, biliposodium alginate, diluent, adhesive, disintegrant, lubricant, flowing aid, antisticking agent and slow releasing agent. Its advantages are high biological utilization rate, low dosage and low by-effect.

The invention discloses a weight losing medicament which comprises phenformin in a pharmaceutical salt form, orlistat and bisacodyl, wherein an effective dosage range of the phenformin is 20mg to 200mg per day; an effective dosage range of the orlistat is 20mg to 1500mg per day; an effective dosage range of the bisacodyl is 5mg to 15mg per day. The weight losing medicament is prepared by the following steps: mixing various components uniformly, and preparing one or several dosage forms in tablets, capsules and oral liquid mixtures to be taken or sequentially taken. Due to the phenformin, orlistat, bisacodyl and medicinal carriers, the weight losing medicament has the effects of inhibiting absorption of the intestinal tract on glucose and fat in foods, reducing blood fat, accelerating metabolism of muscles, fat and other peripheral tissues on the glucose, enhancing reflective peristalsis of rectum to accelerate excrement elimination and shortening the absorption time of the intestinal tract on sugar and fat; abdominal distension, stomachache, diarrhea and other combined effect mechanisms caused by bacteria glycolysis aerogenesis increase because the residence time of sugar and fat which are not absorbed by orlistat in the intestinal tract is extremely long are avoided, so that an aim of losing weight is achieved.

The invention discloses application of phenformin as a skin anti-inflammatory preparation. First discovery finds that the phenformin can be used for obviously inhibiting skin epidermic cells from secreting various inflammatory cell factors including 6 / 8(IL-6, IL-8) and tumor necrosis factors (TNF alpha), and similarly inflammatory response of human skin epithelial cells induced by frequently-used 12-oxy-tetradecanoyl phorbol-13-acetate (TPA) and poly-poly(C) polyinosinic-polycytidylic acid (poly I:C) (immunologic stimulant), so that the phenformin can be used for preventing and curing related diseases of skin inflammation. Therefore, novel application is developed for the phenformin, and new prevention and treatment means is provided for related diseases of skin inflammation.

A compound hypoglycemic medicine in the form of tablet, capsule, particles, or powder for decreasing the sugar, pressure, fat and viscosity of blood is prepared from the fine powder of sulfonylurea medicines, the fine powder of berberine hydrochloride, biliposodium alginate, diluent, adhesive, disintegrant, lubricant, flowing aid, antisticking agent and slow releasing agent. Its advantages are high biological utilization rate, low dosage and low by-effect.